| Similar Articles |
|---|
 |
Chemistry World
June 18, 2007
James Mitchell Crow |
ICI Rejects Bid ICI has rejected a 7.2 billion-pound bid from Dutch chemical firm Akzo Nobel, the British chemical company has revealed.   |
Chemistry World
August 13, 2007 |
ICI Sale Finally Agreed ICI has accepted a takeover offer of 8 billion pounds from chemical conglomerate Akzo Nobel. This 670p per share agreement is Akzo's third approach for ICI in as many months. |
Chemistry World
August 6, 2007
Richard Van Noorden |
Stakes Raised for ICI Dutch chemicals company Akzo Nobel has raised its potential offer for Britain's Imperial Chemical Industries (ICI) to 8 billion pounds (670p per share). |
BusinessWeek
May 14, 2007
Arlene Weintraub |
Schering-Plough Climbs Out Of Its Sickbed Fred Hassan said getting drugmaker Schering-Plough on its feet might take years. Investors are beginning to see the virtues of patience |
The Motley Fool
August 7, 2007
Brian Orelli |
Financing Your Acquisition Schering-Plough is one step closer to financing its $14 billion acquisition of the Organon BioSciences unit of Akzo Nobel, by making an official stock offering. |
The Motley Fool
March 2, 2010
Brian Orelli |
Merck: Poised for Growth and Eager to Go Merck needs its new, stronger, post-acquisition pipeline to pay off. |
Chemistry World
September 29, 2008
James Mitchell Crow |
AkzoNobel to Cut 3500 Jobs AkzoNobel is to cut at least 3500 jobs over the next three years, as it seeks streamline its operations following its 2007 takeover of ICI. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
The Motley Fool
August 28, 2008
Brian Orelli |
Schering and Pfizer Aren't Horsing Around Schering sells some animal health products to Pfizer to keep the EU happy. |
The Motley Fool
November 20, 2009
Brian Orelli |
This Baby Is a Nice Addition A month into an acquisition, and Merck already sees a benefit. |
Pharmaceutical Executive
April 1, 2007 |
Deals: No IPO for Organon Akzo Nobel's plans to spin off its Organon Biosciences unit... Oxford BioMedica will acquire the privately held Oxxon Therapeutics... Jazz Pharmaceuticals has filed a registration statement with the SEC for... etc. |
The Motley Fool
September 22, 2008
Brian Orelli |
Let's Bail Out Pharma Next Schering-Plough is cutting jobs. Maybe the government should help out? |
The Motley Fool
June 4, 2009
Brian Orelli |
MegaMergers Going to the Dogs It looks like Merck isn't sure it'll be able to get its acquisition of Schering-Plough past regulators without doing a little trimming. |
The Motley Fool
November 27, 2007
Brian Orelli |
Ploughing Into Acquisition Rewards Schering-Plough reaps its first New Drug Application from its purchase of Organon. Investors, take note. |
Chemistry World
October 8, 2007
James Mitchell Crow |
Akzo Reveals ICI Plans Akzo Nobel chairman Hans Wijers today gave more detailed plans on the new chemicals giant that would form should the company's proposed acquisition of ICI go ahead. |
The Motley Fool
October 1, 2009
Robert Steyer |
For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business. |
The Motley Fool
October 21, 2008
Brian Orelli |
Schering Buys Great Growth Acquiring Organon Biosciences saves the company from a rough quarter. |
The Motley Fool
February 14, 2008
Brian Orelli |
A Lovey-Dovey Duo Drug companies Schering-Plough and Merck hook up to market a 'hot, hot, hot!' product. |
The Motley Fool
April 4, 2008
Brian Orelli |
Why Is Schering Cutting Now? The latest pharmaceutical company to jump on the cost-cutting bandwagon is Schering-Plough. |
BusinessWeek
April 16, 2007
Arlene Weintraub |
Big Pharma's Animal Spirits Sales of medicine for pets and livestock are giving drugmakers a welcome boost. |
The Motley Fool
October 23, 2007
Brian Orelli |
Schering Ploughed Down Investors punish the pharmaceutical company when it misses Wall Street expectations following 11 consecutive quarters of double-digit sales growth. |
The Motley Fool
February 13, 2008
Brian Orelli |
Schering-Plough Has No Love for the Media Apart from the press bashing regarding the company's cholesterol-lowering drug Enhance, Schering reported a pretty nice quarter. |
Chemistry World
January 8, 2010
Andy Extance |
LED TVs spark trimethylgallium price rise The clamour for supplies of trimethylgallium from GaN light emitting diode manufacturers has caused the first price rise for the metalorganic compound in industry players' memories. |
Chemistry World
October 7, 2015 |
Live blog: Unravelling DNA repair mechanisms takes chemistry Nobel Our live blog explains the vital statistics of the Nobel chemistry prize and the countdown to the award announcement. |
The Motley Fool
April 5, 2007
Toby Shute |
The Definitive Boring Stock: Paint Edition What's the yardstick by which all snooze-inducing events are measured? Watching paint dry? Watching grass grow? As somnolent as these activities may be, the paint and lawn-care industries harbor some surprisingly solid companies. |
Chemistry World
June 22, 2007
Ned Stafford |
Big Pharma Not Interested in 'Male Pill' German drug giant Bayer has officially stopped research and development of a hormonal male contraceptive, yet another sign that the pharma industry has lost interest in developing the so-called 'male pill.' |
The Motley Fool
November 25, 2008
Brian Orelli |
Schering's Peacock Imitation The company lays out its pipeline for investors to see; there are some potential blockbusters waiting there. |
The Motley Fool
March 12, 2008
Brian Orelli |
Will This Drug Help Schering-Plough Recover? FDA approval of Schering-Plough's muscle block medication Bridion looks certain, but will doctors see a need for it? |
The Motley Fool
July 24, 2007
Brian Orelli |
No Pharma Love for Schering A doubling of earnings, but no jump in stock price? Schering investors, take note. |
The Motley Fool
November 4, 2009
Brian Orelli |
An Ode to Schering-Plough Mergers and acquisitions in the pharmaceutical industry are cataloged in a poem. |
The Motley Fool
July 19, 2004
Rich Smith |
Philips' Future Gets Smudged Dutch electronics giant Philips posts great second-quarter earnings, but with too many caveats. |
The Motley Fool
April 24, 2008
Brian Orelli |
Is Schering-Plough the Comeback Kid? Schering posts an OK quarter despite the slowdown in sales of its cholesterol drugs. |
The Motley Fool
October 24, 2005
Stephen D. Simpson |
Vytorin Lifts Schering-Plough While the pharma is now officially in a turnaround phase, the news may already be baked into the stock. |
The Motley Fool
January 31, 2006
Stephen D. Simpson |
Brushing Up on Sherwin-Williams This well-known paint company may be priced to surprise. With conservative numbers in the cash flow model, this looks like a company worth an investor's time. |
The Motley Fool
January 14, 2009
Brian Orelli |
FDA's Bipolar Decision on Schering's Drug Signs point to an approval for Schering-Plough's schizophrenia and bipolar drug Saphris, but there isn't one yet. |
The Motley Fool
April 25, 2008
Tim Beyers |
Who's Buying Now? Insider buys this week: China Security & Surveillance... Escalade... Schering-Plough... Ulta Salon... Vantage Energy Services... |
The Motley Fool
February 9, 2009
Robert Steyer |
Just Say No to Drug Company Mergers There are some reasons to make a big-pharma deal. But there are as many, if not more, reasons to let these companies pursue smaller deals and collaborations rather than become just another part of a hyphenated corporate name. |
Chemistry World
March 13, 2009
Sarah Houlton |
Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time. |
